Spots Global Cancer Trial Database for Pasireotide Treatment for Neuroendocrine Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Pasireotide Treatment for Neuroendocrine Tumor
Official Title: Pasireotide Treatment for Insulin Producing Pancreatic Neuro-endocrine Tumor
Study ID: NCT02779257
Study Description
Brief Summary: Pasireotide binds to somatostatin receptors sst2 and sst5, which can lead to significant hyperglycemia. The investigators would like to administer pasireotide as a treatment for refractory hypoglycemia in the setting of metastatic insulin-producing pancreatic neuro-endocrine tumor.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Contact Details
Name: Kashif M Munir, MD
Affiliation: University of Maryland, Baltimore
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
